With entire supply chains disrupted due to the significant global challenges associated with distributing new Covid-19 vaccines, it has become essential for pharma firms to urgently address blind spots within their supply chains, to minimize significant losses associated with failures in temperature-controlled logistics.
As the pharmaceutical industry loses approximately US$35bn annually due to such failures, the industry finds itself at a crisis point as it battles to mitigate losses from missed handoffs, theft, product spoilage, re-testing and compliance issues.
Cloudleaf’s Digital cold chain reimagined white paper addresses many of the visibility issues challenging the effectiveness of temperature-controlled logistics. The report also explores solutions on how to optimize cold chain for successful product storage and packaging alongside seamless cold chain transit and accurate shipping.
Download this white paper to learn:
- How the lack of visibility in the pharmaceutical supply chain leads to inaccurate predictions, poor planning and delayed decision-making.
- Why prompt action and predictive insights reduce risk and potential loss of product.
- The benefits of implementing a digital visibility platform to attain information on the integrity of pharmaceutical products.